Qdenga (TAK-003) - Dengue Tetravalent Vaccine (Live, Attenuated)

What It Is

Key Differentiator vs Dengvaxia

Mechanism

Goodman & Gilman's notes: "Cross-reactive nonneutralizing antibodies induced by one infection enhance the disease caused by subsequent infection with a heterologous serotype virus. This antibody-dependent enhancement concern has been a significant barrier to vaccine development efforts."

Regulatory Status

• EU/EMA: Approved (2022) for ages 4+ regardless of serostatus
• UK, Indonesia, Brazil, Thailand and 40+ countries: Approved
• Philippines: Approved (March/April 2026 - SEC recommendation)
• USA: NOT FDA-approved for dengue travelers; Dengvaxia remains the only FDA-approved dengue vaccine, limited to seropositive residents of endemic U.S. territories
• As of July 2026: 18.6 million doses distributed across 11 endemic countries

Phase 3 TIDES Trial - 7-Year Results (Completed November 2025)

• N > 20,000 healthy children and adolescents aged 4-16
• Design: Double-blind, randomized, placebo-controlled (2:1 allocation)
• Dosing: 2 doses of 0.5 mL subcutaneously at months 0 and 3
• Duration: 7 years across 5 trial parts

Efficacy Results

• Protection was sustained across all 4 serotypes through 7 years
• The booster was explored as an "exploratory analysis" - not yet part of the standard approved schedule
• The two-dose regimen still recommended as the primary schedule

Safety

• No new safety signals identified over 7 years
• No new signals with the booster dose
• The 2-dose schedule confirmed to provide durable protection

Immunogenicity (From Systematic Review - Naderian et al., 2025)

• TAK-003 showed high seropositivity rates against all 4 DENV serotypes, especially DENV-2 (the backbone serotype)
• Sustained antibody responses observed 3 years after vaccination
• A known concern: serotype-specific efficacy variation - weaker antibody responses to DENV-3 and DENV-4, particularly in seronegative (dengue-naive) individuals
• ADE risk in seronegative recipients is a recognized ongoing concern but less pronounced than with Dengvaxia
• Adverse events mostly mild to moderate: injection site pain, headache

Indications & Use

• Persons aged 4-60 in dengue-endemic regions
• Can be given regardless of prior dengue exposure (this is the key advantage)
• EU-approved for travelers to endemic areas

• Immunocompromised individuals (live vaccine)
• Pregnant or breastfeeding women (precaution - live vaccine)
• History of severe allergic reaction to vaccine components

Limitations & Open Questions

1. Seronegative efficacy gap: Protection against DENV-3 and DENV-4 is lower in dengue-naive individuals; the vaccine primarily primes around the DENV-2 backbone
2. Age range studied: TIDES enrolled ages 4-16; adult data are from smaller studies
3. Not FDA-approved: U.S. travelers cannot access it in the U.S.
4. Long-term ADE risk in seronegatives with DENV-3/4 still under monitoring
5. Booster dose role is exploratory - guidelines on a booster are not yet established

Summary

• 7-year TIDES trial results - Takeda, Nov 2025
• Naderian et al. (2025). "Efficacy, Immune Response, and Safety of Dengue Vaccines in Adolescents: A Systematic Review." Rev Med Virol. PMID: 40195054
• Harrison's Principles of Internal Medicine 22E (2025), Chapter 130 (Travel Vaccines)
• Goodman & Gilman's Pharmacological Basis of Therapeutics, Dengue Virus Vaccine section

WHO Guidelines on Qdenga (TAK-003) in Endemic Regions

Current Governing Documents

Core WHO Recommendations (May 2024 Position Paper)

1. Target Setting - Where to Use It

• WHO recommends TAK-003 only in settings with HIGH dengue disease burden AND high transmission intensity
• Countries with heterogeneous dengue distribution should consider targeted subnational introduction (not necessarily nationwide)
• Not recommended for programmatic use in low-to-moderate dengue transmission settings until the efficacy-risk profile for DENV-3 and DENV-4 in seronegative persons is more thoroughly assessed

"WHO does not recommend the programmatic use of TAK-003 vaccine in low to moderate dengue transmission settings." - WHO Q&A on Dengue Vaccines

2. Target Age Group

3. Dosing Schedule

• 2-dose schedule, 3 months apart (minimum interval; do not reduce)
• If the second dose is delayed for any reason, do not restart the series - administer the second dose at the first available opportunity
• Protection begins 14 days after the first dose and has been demonstrated in the interval between dose 1 and dose 2

4. Pre-vaccination Serostatus Screening

• Adults should be informed about uncertainties regarding efficacy and side effects for DENV-3 and DENV-4 infections in seronegative individuals, given the current lack of trial data for those serotypes in that group
• Where serostatus testing is available, it can be used to inform the individual benefit-risk assessment but is not a programmatic requirement

5. Contraindications

• Pregnancy
• Breastfeeding/lactation
• Immune deficiency states: chemotherapy, high-dose systemic corticosteroids, symptomatic HIV infection, asymptomatic HIV with impaired immune function
• History of severe allergic reaction to any vaccine component

Recommendations for Travelers (Non-Endemic Residents)

• Travelers should be informed that the vaccine may not confer protection against DENV-3 or DENV-4 if they are seronegative
• There is a theoretical risk of severe dengue if seronegative individuals are exposed to DENV-3 or DENV-4 after vaccination
• Pre-vaccination serostatus screening is not required but can be used to better inform individual risk-benefit discussions
• First dose can be given at least 14 days before travel to an endemic country (protection is partially established from dose 1)

GACVS Safety Review - November 2024 (Published March 2025)

• By 12 September 2024: 2,164,503 first doses and 714,298 second doses administered in Brazil's public program
• Main signal identified: anaphylaxis and hypersensitivity reactions - the committee called for ongoing monitoring
• GACVS also noted a case report of symptomatic disease caused by serotype 4 vaccine virus following vaccination
• No new safety signals overturned the existing benefit-risk assessment
• Ongoing requirements: immunological studies to identify triggers, explore mast cell/basophil degranulation mechanisms, and identify risk factors/genetic markers for hypersensitivity

PAHO Position (Americas-Specific)

• Does not recommend countrywide immunization programs with TAK-003 in the Americas at this time (due to limited data on DENV-3/4 in seronegative persons and limited dose availability)
• Supports subnational introduction only in documented high-transmission areas
• Requires any introduction to be considered a pilot program with a robust Phase 4 post-marketing study
• Mandates full informed consent for communities and healthcare providers

Key Unresolved Issues Flagged by WHO

1. DENV-3 and DENV-4 efficacy in seronegatives: The clearest gap - lower neutralizing antibody titers and uncertain real-world protection; potential ADE risk not yet fully quantified
2. Defining "high transmission intensity": Operationally difficult - requires age-specific seroprevalence or incidence data that many countries do not have
3. Booster dose role: Exploratory 7-year TIDES data show benefit (hospitalization efficacy 90.6%), but no WHO guidance yet on a booster dose schedule
4. Long-term safety monitoring: Particularly hypersensitivity/anaphylaxis signal from Brazil rollout

Summary Table

• WHO SAGE Position Paper on Dengue Vaccines, May 2024
• WHO Prequalification of TAK-003, May 2024
• GACVS Safety Update, November 2024 - published March 2025
• Wilder-Smith A et al. (2025). "Dengue Vaccine Development and Deployment into Routine Immunization." Vaccines. PMID: 40432095
• Sáez-Llorens X et al. (2025). "TAK-003: development of a tetravalent dengue vaccine." Expert Rev Vaccines. PMID: 40207772

Dengue Virus - Basics and Serotypes

Classification and Taxonomy

• Family: Flaviviridae
• Genus: Flavivirus
• Closely related to: Zika virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus

1. Insect-specific viruses (mosquito-only)
2. Vertebrate viruses with no arthropod vector (isolated from rodents/bats)
3. Mosquito-borne viruses (dengue belongs here)
4. Tick-borne viruses

Genomic Structure

• Lipid envelope decorated with viral structural proteins
• Three structural proteins:
  • C - Capsid protein: packages the RNA genome
  • prM/M - Membrane protein: involved in viral assembly and maturation
  • E - Envelope glycoprotein: the major surface protein; mediates receptor binding and cell entry; the primary target of neutralizing antibodies
• Seven non-structural (NS) proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5 - involved in RNA replication, immune evasion, and polyprotein processing

1. Why serotype-specific immunity is lifelong
2. Why cross-reactive antibodies are non-neutralizing (and can be enhancing)

Goldman-Cecil Medicine: "Its envelope protein varies by as much as 30 to 40% among the different serotypes. This large divergence is the basis for cross-reactive antibody reactions that are non-neutralizing but potentially enhance the severity of the clinical manifestations."

The Four Serotypes

• Co-circulate simultaneously in hyperendemic regions
• Are transmitted by the same mosquito vector
• Can cause the full spectrum from asymptomatic infection to dengue shock syndrome
• Produce serotype-specific lifelong immunity after recovery

Vector and Transmission

Epidemiology

• ~390-400 million infections per year globally
• ~100 million symptomatic cases annually
• ~40,000 deaths per year from severe dengue
• 3.8 billion people live in dengue-endemic countries
• Endemic in 100+ countries across Southeast Asia, Western Pacific, Central/South America, Africa, Eastern Mediterranean
• 2024 was a record year: >14.6 million cases and >12,000 deaths - Americas alone reported 13 million cases
• Expanding geographically due to climate change and urbanization (now reaching France, Italy, Spain)

Immunology and the ADE Mechanism

Primary Infection

• Immune response generates serotype-specific neutralizing antibodies against the infecting serotype
• These provide lifelong homologous immunity against re-infection with the same serotype
• Also generates cross-reactive antibodies to other serotypes - but these are only temporary (months) and partial

Secondary Infection (Different Serotype)

• The pre-existing cross-reactive antibodies from the first infection recognize but cannot neutralize the new serotype's E protein (due to 30-40% divergence)
• These non-neutralizing antibodies bind the new virus and facilitate its entry into macrophages and monocytes via Fc receptors - this is Antibody-Dependent Enhancement (ADE)
• ADE increases the viral load dramatically and triggers a cytokine storm
• Result: the risk of severe dengue (DHF/DSS) is far higher on secondary infection

Robbins Pathology: "Severe dengue usually occurs in people who have had a previous infection with a different serotype than the one associated with their severe illness. It is more likely to occur with infection of dengue-2 than other serotypes. Antibody-dependent enhancement, in which the cross-reactive antibodies enhance uptake of virus into macrophages via Fc receptors, is thought to increase infectivity of the virus and contribute to severe dengue."

• Infants born to dengue-immune mothers are at high risk - maternal antibodies wane to sub-neutralizing levels, creating the same ADE-permissive window
• Dengvaxia caused harm in seronegative vaccinees - the vaccine primed cross-reactive non-neutralizing antibodies in dengue-naive individuals, mimicking a "virtual first infection," so natural dengue afterwards acted like a severe secondary infection

Clinical Spectrum

Diagnosis

Why 4 Serotypes Matter So Much

1. Sequential exposure to all 4 serotypes is theoretically possible - giving 3 windows of ADE-enhanced severe disease
2. All 4 serotypes co-circulate in hyperendemic cities - a person can be exposed to a different serotype at any time
3. Vaccine development must elicit balanced, neutralizing immunity against all 4 simultaneously - inadequate responses to any one serotype risk creating an ADE-prone state
4. DENV-2's virulence means it disproportionately drives severe disease and death in secondary infections

• Goldman-Cecil Medicine, Dengue Virus (Pathobiology & Definition)
• Robbins, Cotran & Kumar Pathologic Basis of Disease, 10th ed., Dengue section
• Harrison's Principles of Internal Medicine 22E (2025), Chapter on Emerging Infectious Diseases
• Rosen's Emergency Medicine: Concepts and Clinical Practice, Dengue Virus section
• Sherris & Ryan's Medical Microbiology, 8th ed., Dengue section
• Fitzpatrick's Dermatology, Dengue Virus - Etiology and Pathogenesis